title: Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.
abstract: Long-term kidney transplant outcomes remain suboptimal, delineating an unmet medical need. Although current immunosuppressive therapy in kidney transplant recipients is effective, dosing is conventionally adjusted empirically on the basis of time after transplant or altered in response to detection of kidney dysfunction, histologic evidence of allograft damage, or infection. Such strategies tend to detect allograft rejection after significant injury has already occurred, fail to detect chronic subclinical inflammation that can negatively affect graft survival, and ignore specific risks and immune mechanisms that differentially contribute to allograft damage among transplant recipients. Assays and biomarkers that reliably quantify and/or predict the risk of allograft injury have the potential to overcome these deficits and thereby, aid clinicians in optimizing immunosuppressive regimens. Herein, we review the data on candidate biomarkers that we contend have the highest potential to become clinically useful surrogates in kidney transplant recipients, including functional T cell assays, urinary gene and protein assays, peripheral blood cell gene expression profiles, and allograft gene expression profiles. We identify barriers to clinical biomarker adoption in the transplant field and suggest strategies for moving biomarker-based individualization of transplant care from a research hypothesis to clinical implementation.
authors.affiliation: Renal Division, Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Madhav C
authors.initials: MC
authors.lastname: Menon
authors.affiliation: Renal Division, Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Barbara
authors.initials: B
authors.lastname: Murphy
authors.affiliation: Renal Division, Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York peter.heeger@mssm.edu.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Heeger
mesh_terms: D000906:Antibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D005544:Forecasting; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000097:blood* / Q000276:immunology*; D018570:Risk Assessment; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000906:Antibodies; D015415:Biomarkers; D006680:HLA Antigens
keywords: biomarker; transplant outcomes; transplantation